Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study

Infectious Agents and Cancer

Volumn 7, Issue 1, 2012, Pages

  Munk, Ane Cecilie ^a   Øvestad, Irene Tveiterås ^a   Gudlaugsson, Einar ^a   Løvslett, Kjell ^a   Fiane, Bent ^a   Van Diermen Hidle, Bianca ^a   Kruse, Arnold Jan ^b   Skaland, Ivar ^a   Janssen, Emiel A M ^a   Baak, Jan P A ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CIN2 3; Clinical factors; Condom use; High risk HPV; HPV16; Regression

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER GRADING; CANCER REGRESSION; COHORT ANALYSIS; COLPOSCOPY; CONDOM; CONTRACEPTION; DISEASE COURSE; FEMALE; FOLLOW UP; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PARITY; PATIENT IDENTIFICATION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUNCH BIOPSY; SEXUAL BEHAVIOR; SMOKING; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; WART VIRUS;

EID: 84868216988     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-7-30     Document Type: Article

References (45)

1. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. Coutlee F, Ratnam S, Ramanakumar AV, Insinga RR, Bentley J, Escott N, Ghatage P, Koushik A, Ferenczy A, Franco EL, J Med Virol 2011 83 6 1034 1041 10.1002/jmv.22081 21503917
2. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N, J Pathol 1999 189 1 12 19 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482
3. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. Bosch FX, de Sanjose S, J Natl Cancer Inst Monogr 2003 31 3 13 12807939
4. Understanding and responding to disparities in HIV and other sexually transmitted infections in African Americans. Aral SO, Adimora AA, Fenton KA, Lancet 2008 372 9635 337 340 10.1016/S0140-6736(08)61118-6 18657713
5. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Syrjanen K, Hakama M, Saarikoski S, Vayrynen M, Yliskoski M, Syrjanen S, Kataja V, Castren O, Sex Transm Dis 1990 17 1 15 19 2154865
6. Natural history of cervicovaginal papillomavirus infection in young women. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD, N Engl J Med 1998 338 7 423 428 10.1056/NEJM199802123380703 9459645
7. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS, Lancet 2001 357 9271 1831 1836 10.1016/S0140-6736(00)04956-4 11410191
8. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB, N Engl J Med 1992 327 18 1272 1278 10.1056/NEJM199210293271804 1328880
9. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. Rozendaal L, Westerga J, van der Linden JC, Walboomers JM, Voorhorst FJ, Risse EK, Boon ME, Meijer CJ, J Clin Pathol 2000 53 8 606 611 10.1136/jcp.53.8.606 11002764
10. Natural history of cervical intraepithelial neoplasia: a critical review. Ostor AG, Int J Gynecol Pathol 1993 12 2 186 192 10.1097/00004347-199304000- 00018 8463044
11. Behavior of moderate cervical dysplasia during long-term follow-up. Nasiell K, Nasiell M, Vaclavinkova V, Obstet Gynecol 1983 61 5 609 614 6835614
12. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. Baak JP, Kruse AJ, Robboy SJ, Janssen EA, van Diermen B, Skaland I, J Clin Pathol 2006 59 10 1017 1028 10.1136/jcp.2005.027839 16679355
13. Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Ovestad IT, Gudlaugsson E, Skaland I, Malpica A, Kruse AJ, Janssen EA, Baak JP, Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2010 23 9 1231 1240 10.1038/modpathol.2010.109
14. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. International Collaboration of Epidemiological Studies of Cervical Cancer, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009 18 4 1060 1069 23151416
15. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, Shah KV, Meijer CJ, Bosch FX, Lancet 2002 359 9312 1093 1101 10.1016/S0140-6736(02)08151-5 11943256
16. Cervical cancer and use of hormonal contraceptives: a systematic review. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Plummer M, Beral V, Lancet 2003 361 9364 1159 1167 10.1016/S0140-6736(03)12949-2 12686037
17. Active and passive cigarette smoking and the risk of cervical neoplasia. Trimble CL, Genkinger JM, Burke AE, Hoffman SC, Helzlsouer KJ, Diener-West M, Comstock GW, Alberg AJ, Obstet Gynecol 2005 105 1 174 181 10.1097/01.AOG. 0000148268.43584.03 15625160
18. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, Wilgus B, Yutzy W, Daniel R, Shah K, et al. Clinical cancer research: an official journal of the American Association for Cancer Research 2005 11 13 4717 4723 10.1158/1078-0432.CCR-04-2599
19. Heterogeneity of high grade cervical intraepithelial neoplasia related to HPV16: Implications for natural history and management. Wentzensen N, Walker J, Schiffman M, Yang HP, Zuna RE, Dunn ST, Allen RA, Zhang R, Sherman M, Gold MA, Wang SS, Int J Cancer 2013 Jan 1 132 1 148 154 10.1002/ijc.27577
20. Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions. Baak JP, Kruse AJ, Garland SM, Skaland I, Janssen EA, Tabrizi S, Fagerheim S, Robboy S, Nilsen ST, Am J Surg Pathol 2005 29 8 1062 1066 16006801
21. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC, The lancet oncology 2008 9 5 425 434 10.1016/S1470-2045(08)70103-7 18407790
22. CO2 laser conization for cervical intraepithelial neoplasia grade II-III: complications and efficacy. Hagen B, Skjeldestad FE, Bratt H, Tingulstad S, Lie AK, Acta Obstet Gynecol Scand 1998 77 5 558 563 10.1080/j.1600-0412.1998. 770515.x 9654180
23. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E, Lancet 2006 367 9509 489 498 10.1016/S0140-6736(06)68181-6 16473126
24. Pregnancy outcome in women before and after cervical conisation: population based cohort study. Albrechtsen S, Rasmussen S, Thoresen S, Irgens LM, Iversen OE, BMJ 2008 337 1343 10.1136/bmj.a1343 18801869
25. Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. Barken SS, Rebolj M, Andersen ES, Lynge E, Int J Cancer 2012 130 10 2438 2444 10.1002/ijc.26248 21702034
26. Cervical intraepithelial neoplasia grade 3 lesions can regress. Munk AC, Kruse AJ, van Diermen B, Janssen EA, Skaland I, Gudlaugsson E, Nilsen ST, Baak JP, APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 2007 115 12 1409 1414 18184413
27. Epidemiologic classification of human papillomavirus types associated with cervical cancer. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, N Engl J Med 2003 348 6 518 527 10.1056/NEJMoa021641 12571259
28. Carcinogenicity of human papillomaviruses. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Lancet Oncol 2005 6 4 204 10.1016/S1470-2045(05)70086-3 15830458
29. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. Kjaer SK, Frederiksen K, Munk C, Iftner T, J Natl Cancer Inst 2010 102 19 1478 1488 10.1093/jnci/djq356 20841605
30. Annual Report Cervical Cancer Screening 2008. Steen R, Johansen BK, Skare G, Haldorsen T, Eriksen T, Waage R, Molund IM, Cancer Registry of Norway 2009
31. WHO, IARC Classification of Tumors of the Breast and Female Genital Organs, vol. Book 4 IARCPress, Lyon 2003
32. Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. Kruse AJ, Baak JP, de Bruin PC, Jiwa M, Snijders WP, Boodt PJ, Fons G, Houben PW, The HS, J Pathol 2001 193 1 48 54 10.1002/1096-9896(2000)9999:9999<::AID-PATH719>3.0.CO;2-E 11169515
33. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. Soreide K, J Clin Pathol 2009 62 1 1 5 10.1136/jcp.2008.061010 18818262
34. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M, J Natl Cancer Inst 2005 97 14 1072 1079 10.1093/jnci/dji187 16030305
35. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM, Int J Cancer 2007 121 3 621 632 10.1002/ijc.22527 17405118
36. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM, Int J Cancer 2011 128 4 927 935 10.1002/ijc.25396 20473886
37. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J, Westenend PJ, Meijer CJ, Int J Cancer 2003 107 5 811 816 10.1002/ijc.11474 14566832
38. A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Rousseau MC, Franco EL, Villa LL, Sobrinho JP, Termini L, Prado JM, Rohan TE, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2000 9 5 469 476 23151416
39. Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. Olsen AO, Dillner J, Skrondal A, Magnus P, Epidemiology 1998 9 3 346 349 10.1097/00001648-199805000-00022 9583429
40. Nicotine and cotinine in the cervical mucus of smokers, passive smokers, and nonsmokers. McCann MF, Irwin DE, Walton LA, Hulka BS, Morton JL, Axelrad CM, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1992 1 2 125 129 23151416
41. Tobacco smoking and the uterine cervix: cotinine in blood, urine and cervical fluid. Poppe WA, Peeters R, Daenens P, Ide PS, Van Assche FA, Gynecol Obstet Invest 1995 39 2 110 114 10.1159/000292390 7737579
42. Smoking and high-risk sexual behavior among young adults in Hong Kong. Lam TH, Stewart SM, Ho LM, J Behav Med 2001 24 5 503 518 10.1023/A:1012227728232 11702362
43. Immunosuppressive mechanisms in semen: implications for contraception. Kelly RW, Hum Reprod 1995 10 7 1686 1693 8582962
44. Human semen: the biological basis of sexual behaviour to promote human papillomavirus infection and cervical cancer. Wang X, Zhuang J, Wu K, Xu R, Li M, Lu Y, Med Hypotheses 2010 74 6 1015 1016 10.1016/j.mehy.2010.01.009 20138438
45. The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3. Ovestad IT, Gudlaugsson E, Skaland I, Malpica A, Munk AC, Janssen EA, Baak JP, J Clin Pathol 2011 64 4 303 307 10.1136/jcp.2010.083626 21421698